Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of precision medicines for metabolic and endocrine disorders. Leveraging proprietary covalent chemistry platforms, Tyra aims to target disease-relevant transcription factors and nuclear receptors that have historically been difficult to modulate with small molecules. The company’s pipeline includes several preclinical and early‐stage clinical candidates designed to address conditions such as nonalcoholic steatohepatitis (NASH) and other metabolic diseases, with a particular focus on improving liver function and systemic metabolic profiles.

Founded in 2021 by leading life science investors and researchers, Tyra Biosciences is headquartered in San Diego, California—a hub for biotechnology innovation. The company was built on a foundation of collaborative research, combining deep expertise in medicinal chemistry with translational biology to accelerate the development of novel therapies. Tyra’s scientific team applies an integrated approach, from target identification and validation through medicinal chemistry optimization and in vivo proof-of-concept studies.

Under the leadership of Chief Executive Officer Brian Lian, Tyra has assembled a management team with extensive experience in drug discovery, clinical development and regulatory strategy. The company continues to advance its most advanced programs toward clinical proof of concept while expanding its discovery efforts through ongoing partnerships and strategic collaborations. By focusing on innovative mechanisms of action and precision targeting, Tyra Biosciences seeks to address significant unmet needs in metabolic and endocrine diseases.

Key Stats

• Today's Range: $10.38 to $11.19
• 50-Day Range: $8.82 to $10.92
• 52-Week Range: $6.42 to $29.60
• Volume: 104,279 shs
• Average Volume: 291,903 shs
• Market Capitalization: $551.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.83
• Consensus Rating: Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 394th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tyra Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.57) to ($2.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tyra Biosciences has recently decreased by 99.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tyra Biosciences has recently decreased by 99.50%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.37

News Sentiment

Tyra Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tyra Biosciences this week, compared to 4 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $628,358.00 in company stock.

Percentage Held by Insiders

15.20% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TYRA Stock Analysis - Frequently Asked Questions

How have TYRA shares performed this year?

Tyra Biosciences' stock was trading at $13.90 on January 1st, 2025. Since then, TYRA shares have decreased by 25.3% and is now trading at $10.39.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an IPO on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

Who are Tyra Biosciences' major shareholders?

Top institutional shareholders of Tyra Biosciences include Canaan Partners XI LLC (6.80%) and Public Employees Retirement System of Ohio (0.03%). Insiders that own company stock include Todd Harris, Nina S Kjellson, Daniel Bensen, Mva Investors, Llc, Gilla Kaplan and Alan Fuhrman.
View institutional ownership trends.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tyra Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tyra Biosciences: $30.83
• High Price Target: $33.00
• Low Price Target: $28.00
• Potential Upside/Downside: +196.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.90%
• Return on Assets: -25.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.78
• Quick Ratio: 22.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.78 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 53,090,000
• Free Float: 45,020,000
• Market Cap: $551.61 million
• Optionable: Optionable
• Beta: 1.07